Kytril

Granisetron, the active ingredient in Kytril, is a 5‑HT3 receptor antagonist presented as an injectable solution for intravenous use. It is employed to prevent and treat nausea and vomiting that occur with chemotherapy, radiation therapy, and postoperative recovery in adult patients, including both acute and delayed phases of emesis.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable global logistics for this essential antiemetic.

Kytril, a selective 5‑HT3 receptor antagonist, acts on the emetic pathways triggered by chemotherapy, radiation or surgery.

Chemotherapy‑induced nausea and vomiting: prevents and reduces acute and delayed episodes in patients receiving emetogenic chemotherapy. Radiation‑induced nausea and vomiting: controls nausea and vomiting associated with therapeutic radiation. Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Injection‑site pain or erythema - Mild hypotension

Serious or Rare Side Effects: - Cardiac arrhythmia or QT‑interval prolongation - Severe allergic reaction (anaphylaxis) - Serotonin syndrome when combined with other serotonergic agents - Rare cases of severe hypotension or syncope

Kytril should be used with caution in patients with pre‑existing cardiac conditions.

Assess cardiac risk: monitor ECG in patients with known QT prolongation. Review concomitant medications: avoid or closely monitor other QT‑prolonging drugs. Use with caution in hepatic impairment: adjust monitoring as needed. Pregnancy and breastfeeding: consider risk‑benefit ratio; limited data are available. Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Kytril may interact with several drug classes.

Major Interactions (Avoid): - Other QT‑prolonging agents: increased risk of arrhythmia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce efficacy.

Moderate Interactions (Monitor Closely): - Serotonergic drugs (e.g., SSRIs, triptans): potential serotonin syndrome. - Anticholinergic agents: may worsen constipation. - Certain anesthetics (e.g., propofol): may enhance hypotensive effect.